S1P may be a potential target for cerebral blood alterations 9 September 2021 | By Anna Begley (Drug Target Review) Sphingosine-1 phosphate was found to regulate blood glow in cerebral blood vessels in mice, presenting a potential therapeutic target.
Researchers simulate hepatitis B infection using computational method 8 September 2021 | By Anna Begley (Drug Target Review) The new study modelled the process of capsid disassembly of the hepatitis B virus at an atomic level to help develop targeted therapies.
Genomic study uncovers causes of lung cancer in non-smokers 8 September 2021 | By Anna Begley (Drug Target Review) An NIH study used whole genome sequencing to describe three molecular subtypes of lung cancer in non-smokers, possibly improving treatments.
Stem-like T cells could improve immunotherapy treatments 7 September 2021 | By Anna Begley (Drug Target Review) Targeting stem-like T cells within certain lymph nodes could improve the number of cancer patients that respond to immunotherapy treatments.
Researchers engineer “mini” CRISPR genome editing system 7 September 2021 | By Anna Begley (Drug Target Review) Stanford researchers have developed a multi-purpose “mini” CRISPR system, called CasMINI, that may be easier to deliver into human cells.
Scientists discover mechanism behind cardiac hypertrophy 6 September 2021 | By Anna Begley (Drug Target Review) New research has uncovered a mechanism underlying cardiac hypertrophy in mice, spurring novel avenues for potential treatments.
RN7SL1 RNA shown to activate T cells to fight against cancer 6 September 2021 | By Anna Begley (Drug Target Review) A new study found that the RNA RN7SL1 can activate T cells to seek out cancer cells, potentially improving cellular treatments.
Genetic defect in IBD patients linked to gut leakiness 6 September 2021 | By Anna Begley (Drug Target Review) A genetic defect in patients with inflammatory bowel disease (IBD) was found to affect how intestinal epithelial cells maintain a barrier.
Innovative brain model provides patient-specific Alzheimer’s insights 3 September 2021 | By Anna Begley (Drug Target Review) Researchers have turned human stem cells into brain cells to create a new model that can predict cognitive decline rate on an individualised level.
New screening method identifies COVID-19 protein inhibitor 3 September 2021 | By Anna Begley (Drug Target Review) Researchers use fast and cost-effective technology to identify the viral protein inhibitor Mpro as a potential drug against COVID-19.
IAIPs shown to reduce ischemic stroke damage in pre-clinical study 2 September 2021 | By Anna Begley (Drug Target Review) Inter-alpha inhibitor proteins (IAIP) demonstrated efficiency in reducing damage from an ischemic stroke, reveals pre-clinical study.
Immune cell changes detected in Waldenstrom macroglobulinemia (WM) 2 September 2021 | By Anna Begley (Drug Target Review) A new study has found mutations originating in blood progenitor cells, possibly leading to Waldenstrom macroglobulinemia (WM) therapies.
Controlling HSP27 “switch” could be key to sepsis therapeutics 1 September 2021 | By Anna Begley (Drug Target Review) Study reveals that the HSP27 protein plays a role in regulating blood vessel leakage, providing new targets for drugs against sepsis.
DNA mechanism discovery may open up Huntington’s disease therapies 1 September 2021 | By Anna Begley (Drug Target Review) Scientists unveiled how a DNA repair protein may prevent Huntington’s disease, presenting a new target in future therapies.
Innovative algorithm could help advance single-cell genomics 1 September 2021 | By Anna Begley (Drug Target Review) Researchers have developed a novel algorithm, “scArches”, that can compare data on single-cell genomics to better understand diseases.
